SCHEMBL5418985

SCHEMBL5418985

O=C(NS(=O)(=O)C=Cc1ccccc1)c1ccc(F)cc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.49
PKM P14618 1/20 0.49
FLT1 P17948 4/20 0.47
FLT4 P35916 4/20 0.47
KDR P35968 4/20 0.47
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 1/20 0.45
ALDH1A1 P00352 1/20 0.45
POLB P06746 1/20 0.45
GAA P10253 1/20 0.45
HSD17B10 Q99714 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
HPGD P15428 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
PYGL P06737 2/20 0.43
CYP2D6 P10635 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HTT P42858 1/20 0.42
PTGES2 Q9H7Z7 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5418975 1.00 KMT2A (0.49) KMT2APKMFLT1FLT4KDR
SCHEMBL5411552 0.90 FLT1 (0.53) FLT1FLT4KDRHPGDPYGL
SCHEMBL5411563 0.90 FLT1 (0.53) FLT1FLT4KDRHPGDPYGL
SCHEMBL5420988 0.89 PTGES2 (0.54) FLT1FLT4KDRHPGDPYGL
SCHEMBL5420981 0.89 PTGES2 (0.54) FLT1FLT4KDRHPGDPYGL
SCHEMBL5414126 0.89 FLT1 (0.51) KMT2AFLT1FLT4KDRHPGD
SCHEMBL5414134 0.89 FLT1 (0.51) KMT2AFLT1FLT4KDRHPGD
SCHEMBL4618981 0.87 FLT1 (0.61) KMT2AFLT1FLT4KDRKDM4E
SCHEMBL4618989 0.87 FLT1 (0.61) KMT2AFLT1FLT4KDRKDM4E
SCHEMBL5407436 0.86 PTGES2 (0.54) FLT1FLT4KDRHPGDPYGL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US claimed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US claimed
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270874-A1 Styrylsulfonamides STS, SULT1E1, BRCA1 KMT2A 2935/4885PKM 793/4885FLT1 4126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.